Previous reports have documented an attenuated p53 response to DNA damage in hepatocytes isolated from enzyme-altered foci (EAF). Here, we have studied this p53 response in vivo in rats with EAF. These animals received repeated doses of diethylnitrosamine (DEN) for 6 weeks and a challenging dose 24 h before death. Liver sections were then analysed using an immunohistological procedure for p53, or a double-staining procedure for p53 and glutathione-S-transferase pi (GST-P). In control rats or rats with EAF not given the challenging dose of DEN, there was no p53 staining. In control rats, only given the challenging dose of DEN, there was a centrilobular p53 nuclear staining that co-localized with TUNEL staining. In an experiment involving four rats with EAF 389 ⍨ 39 hepatocytes/mm 2 of non-EAF tissue stained positively for p53, while the corresponding value for EAF tissue was 27.6 ⍨ 7.5. Thus, p53-positive cells were 14.6-fold more frequent in non-EAF than in EAF tissue. In many EAF no p53-positive cells were seen at all and 83% of the EAF demonstrated <20% of the number of p53-positive cells seen in non-EAF tissue. Very few EAF had as high a proportion of p53-positive cells as did the average non-EAF tissue. EAF >0.06 mm 2 had significantly fewer p53-positive cells than smaller EAF. The ratio of p53 expression in non-EAF tissue and large EAF was 32.6. In a control experiment, four EAF-bearing rats were used as donors to prepare primary cultures of hepatocytes. After 24 h of exposure to DEN, many of the cultured cells became p53-positive. Among GST-P-negative hepatocytes, 12.8% were p53-positive, whereas only 0.25% of the GST-P-positive hepatocytes were p53-positive. Literature data suggest that the altered xenobiotic metabolism in EAF may give rise to a 3-4-fold difference in DNA damage between non-EAF and EAF tissues. It is concluded that GST-P-positive EAF hepatocytes have an attenuated p53 response to DNA damage. This attenuated response may facilitate clonal expansion of EAF under stress induced by DNA-damaging chemicals.
Introduction
p53 is a transcription factor that accumulates in the nucleus in response to DNA damage induced by, for example, chemical carcinogens. This protein activates the transcription of many genes, including p21 WAF1 which encodes a cyclin-dependent kinase inhibitor. p53-induced p21 WAF1 may prevent cells with damaged DNA from replicating (1, 2) . p53 may also trigger apoptosis, presumably by activating genes related to ROS production and subsequent GSH depletion (3) . The apparent importance of p53 as a tumour suppressor is indicated by the findings that~50% of all human tumours carry a mutated p53 gene and that certain cancer-prone families demonstrate a mutated p53 allele (4) .
Treatment of rats with a carcinogen results in the development of numerous liver lesions called enzyme-altered foci (EAF*) (5) . There are many indications that these early lesions are adaptive in nature (6) . One of the most conspicuous of these indications are alterations in xenobiotic metabolism, which render EAF hepatocytes resistant to toxicants. One xenobiotic metabolizing enzyme, glutathione-S-transferase pi (GST-P), which can inactivate many reactive xenobiotic metabolites, is not detectable in normal rat liver tissue, but is expressed at a high level in most EAF. Thus, this enzyme is commonly used as a marker for EAF (5) . A few EAF may eventually develop into hepatocellular carcinomas and a surprising finding is that p53 mutations are rarely found in such tumours in the rat (7, 8) .
Previously, we have studied p53 expression in hepatocytes isolated from EAF-bearing rats. We found that EAF hepatocytes in primary culture did not respond to DNA-damaging agents, such as diethylnitrosamine (DEN), with an increased expression of p53 (9) (10) (11) . Non-EAF hepatocytes in the same culture responded readily with induction of p53 within 24 h and none of these cells replicated its DNA. In agreement with the hypothesis that an altered xenobiotic metabolism confers resistance to xenobiotics on EAF hepatocytes, we found indications of DNA damage four times more often in non-EAF hepatocytes than in EAF hepatocytes. However, a significant number of EAF hepatocytes appeared to have damaged DNA and some of these cells replicated their DNA. These data were in agreement with in vivo data on 'replicative foci' induced by 2-AAF in rat liver, and with the finding that cells in these foci containing DNA adducts could replicate (12) .
Based on our findings, we proposed that p53 plays an important role in adaptive responses induced by genotoxic carcinogens in rat liver. We suggest that a lack of induction of p53 in EAF hepatocytes in response to DNA damage may facilitate the clonal expansion of these cells. This suggestion is based on the assumption that p53 can induce a permanent stop in the cell cycle in many non-EAF hepatocytes (cf. ref. 13 ) and/or trigger apoptosis, whereas EAF hepatocytes may replicate even when exposed to high levels of genotoxic compounds. If such EAF cells can be eliminated by apoptotic mechanisms after the exposure and if the exposure to the toxicant is relatively short, the risk for malignancy should remain low.
In this investigation we have challenged EAF-bearing rats with a single dose of DEN 24 h before death, and examined the p53 response in non-EAF and EAF tissue using immunohistological procedures. We have also examined the responses of non-EAF and EAF hepatocytes to DEN treatment obtained in vitro.
Materials and methods

Treatment of donor animals
Female Sprague-Dawley rats were injected i.p. with DEN (0.30 mmol/kg body wt) 24 h after birth. At 3 weeks of age, the animals were weaned and thereafter injected i.p. with the same dose of DEN once each week. After 6-10 doses of DEN, the rats were used as donor animals or for immunohistological studies. Most rats used for immunohistology also received an injection of DEN (0.60 mmol/kg body wt) 24 h prior to death. In control immunohistological experiments untreated rats were challenged by an injection of DEN (0.60 mmol/kg body wt) 24 h prior to death.
Immunohistological staining
Rats were subjected to surgery under light ether anaesthesia. Their livers were perfused with 3.7% buffered formaldehyde at 37°C for 1.5 h and subsequently placed in formalin for 24 h. After fixation the sections were processed for paraffin sectioning. The slides (in citrate buffer) were treated with microwaves five times for 5 min each time prior to staining. Sections were single-or double-stained with polyclonal antibodies directed towards GST-P and monoclonal antibodies (Pab 240) against p53 (Oncogene Science) as follows. After incubation with anti-p53 (with a dilution of 1/100 under standard conditions) and anti-GST-P overnight, the slides were exposed to anti-rabbit secondary antibodies (dilution 1/100) for 1.5 h. GST-P staining was visualized using an alkaline phosphatase-conjugated secondary antibody and New Fuchsin. p53 was visualized using the EnVisionϩ TM peroxidase kit (Dako, Denmark) with 3-diaminobenzidine tetrahydrochloride as substrate. Some sections were stained with terminal deoxynucleotidyl transferase using TdT FragEL TM apoptosis kit (Calbiochem).
Primary cultures and immunocytology
Hepatocytes were isolated using the collagenase perfusion technique and cultured as described previously (9, 14) . In brief, the cells were cultured for 1.5 h in complete medium containing serum. This medium was then replaced by serum free medium containing DEN (0.3 mM) for 24 h. Fixed cells were double-stained with polyclonal rabbit anti-GST-P antibodies and monoclonal antibodies (Pab 240) towards p53 (Oncogene Science; at a dilution of 1/100). Secondary antibodies were then used, and finally, peroxidase-rabbit antiperoxidase complexes and alkaline phosphatase-mouse anti-alkaline phosphatase complexes. Peroxidase activity was visualized with 3-diaminobenzidine tetrahydrochloride and alkaline phosphatase with New Fuchsin (Dako, Sweden) as substrates. GST-P was used as a marker for distinguishing between EAF (positive) and non-EAF (negative) hepatocytes. The fraction of cells that expressed the GST-P marker varied from 5 to 17% in the different animals. The percentage marker-positive cells was determined by counting at least 500 cells with typical hepatocyte morphology from randomly-selected fields on each plate. Immunoprecipitation and Western blot analysis was performed essentially as described in (15) . p53 was detected with monoclonal antibody Pab 240 (Oncogene Science) and rabbit p53 antibody CM-1 (Novocastra Laboratories, Newcastle).
Evaluation of the in situ data presented in Tables I-IV
Stained liver sections (a total of at least 46 mm 2 from each rat) were analysed microscopically. The area, volume and volume fraction of EAF were calculated using software based on the method of Pugh et al. (16) . All GST-P-positive EAF Ͼ0.003 mm 2 were analysed and the total EAF area analysed per rat varied between 1.96 and 3.03 mm 2 . Twenty randomly selected GST-P negative fields (non-EAF tissue), each spanning at least one periportal and one perivenous zone, were also analysed in each section. In each rat at least 3.43 mm 2 non-EAF tissue was analysed. p53 expression was assessed by counting the number of p53-positive cells in each EAF and non-EAF fields. Foci were also divided into three groups according to size and the volume fraction of each group was determined.
Results
In control experiments involving untreated rats there was no staining for p53. In rats treated with DEN 24 h before death several p53-positive hepatocytes were seen. The staining was localized to nuclei ( Figure 1A and B) in perivenous hepatocytes ( Figure 1A ). Pab 240 was used in most stainings. CM-1 was also tested and gave similar results. Serial sections without p53 antibodies were entirely negative. In sections from livers fixed with standard procedures (i.e. not perfused with formalin) the p53 staining was weaker or absent. Figure 2 shows that there was a co-localization in the lobuli between p53 positive cells and cells stained by TdT activity. The number of p53 expression in liver tissue and EAF Fig. 3 . A p53-negative EAF from a DEN-treated rat. The liver section was double-stained for GST-P and p53. GST-P-positive EAF (red cytoplasm) with surrounding non-EAF tissue are seen. In the non-EAF tissue, several p53-positive hepatocytes (brown nuclei) can be seen. In EAF tissue no p53-positive nuclei can be seen.
TUNEL-positive cells were few as compared with the number of p53-positive cells.
In control experiments involving EAF-bearing animals which did not receive a challenging dose of DEN, there was no staining for p53. Both non-EAF tissue and EAF were totally negative for p53. A recent study demonstrated that single exposure to DEN-induced DNA adducts 6 h later, with maximal levels of adducts being obtained at 24 h (17). We administered the challenging dose 24 h prior to sacrifice.
GST-P was used as a marker for EAF and liver sections were double-stained for GST-P and p53. In the double-stained sections, GST-P-positive areas were clearly seen, as were p53 positive nuclei. p53-positive nuclei were observed in GST-Pnegative, as well as in GST-P-positive areas. On a cellular level p53 staining was distributed in the same fashion as that seen in EAF-free rats, i.e. such staining was only present in nuclei of hepatocytes. In serial sections subjected to staining for p53 only or to double-staining, there were no apparent differences in the number of p53-positive cells. The number of p53-positive cells varied with the size of the challenging dose of DEN. Necrogenic doses induced a very high frequency of p53 staining.
In non-EAF tissue in the livers of EAF-bearing rats the distribution of p53-positive cells in the lobules was uneven and similar to that observed in EAF-free rats. p53-positive hepatocytes were present primarily outside GST-P-positive areas. Figure 3 shows an EAF in which no p53-positive nuclei can be seen, as can the relatively frequent occurence of p53-positive nuclei in non-EAF tissue. There were also EAF with p53-positive cells. Figure 4 depicts a GST-P-positive EAF containing several p53-positive nuclei.
Even doses which induced signs of necrosis in large non-EAF areas and a p53 response in the majority of non-EAF hepatocytes, induced p53 in only a few EAF hepatocytes. Figure 5 shows part of an EAF from a rat challenged with a necrogenic dose (1.8 mmol/kg) of DEN. In this case the section was stained for p53 only and a more concentrated solution of the primary antibody against p53 was used, which resulted in faint staining of non-EAF cytoplasm. The EAF can be seen as virtually unstained islands in heavily stained non-EAF tissue.
In Figures 3 and 4 and Tables I-IV we present data from an experiment involving four rats. Each rat received 6 weekly doses of DEN and was then challenged with a single DEN dose of 0.60 mmol/kg body weight 24 h prior to death. Only GST-P-positive EAF Ͼ0.003 mm 2 were examined. There were no macroscopic nodules or tumours present in the livers of these rats. Microscopic examination revealed, on the other hand, many GST-P-positive EAF. No EAF was Ͼ0.3 mm 2 . In Table I certain parameters for the GST-P-positive EAF in these rats are presented. The numbers and the volume fractions were as expected from previous investigations. 2 . From rat to rat, there was a certain co-variation of the frequency of p53-positive cells in these two types of tissues. Thus, the ratios of the non-EAF to EAF values were slightly more stable, varying between 11.2 and 18.0. The mean of these four ratios was 14.6. Thus, assuming that EAF tissue contains on average as many hepatocytes/unit area as non-EAF tissue, p53-positive hepatocytes were 14.6 times more frequent in non-EAF than in EAF tissue. Table II also documents the number of EAF which can be regarded as 'p53-negative'. All EAF with Ͻ75 p53-positive cells/mm 2 (which is~20% of the average number in non-EAF tissue) were assigned to this category (Figure 3 ). In these four rats 83.3% of the EAF were p53-negative. Almost all of the rest also demonstrated a lower proportion of p53-positive cells than that seen in non-EAF tissue (Figure 4 ). Very few EAF per rat liver exhibited a frequency of p53-positive cells as high as that of the average non-EAF tissue (390 p53-positive cells/mm 2 ). Among EAF with a higher frequency, all except one were Ͻ0.06 mm 2 . This large EAF (found in rat no. 2) showed signs of regression, with weak GST-P-staining and many cells demonstrating signs of degenerative alterations.
There was no consistent correlation between the volume fraction of EAF (Table I ) and the ratio of p53 expression presented in Table II . However, the highest ratio was found for the rat with the largest volume fraction, while the lowest ratio was associated with the rat with the smallest volume fraction. This suggests a relationship between p53 expression and EAF size, so for further analysis we subdivided the EAF into categories by size.
In Table III , p53 expression in three groups of EAF, called here small, medium and large EAF, are given. In three of the four rats, large EAF (0.06-0.294 mm 2 ) had fewer p53-positive hepatocytes than did small and medium EAF. The ratios of p53-positive cells in non-EAF tissue, on the one hand, and in these three groups of EAF, on the other, are also given. For small and medium EAF, the ratios were similar and ranged between 6.9 and 15.9. This variation reflected differences between rats, rather than differences between the small and medium EAF within a single rat liver. For large EAF the ratio varied between 15.3 and 51.1. In three of the rats this ratio was markedly higher than for the other two groups. If a single large EAF (in rat no. 2; as mentioned above), containing a very high number of p53-positive cells, was excluded, the average number of p53-positive cells in large EAF was altered from 25.8 to 8.1 cells/mm 2 (Table III) . Table IV summarizes the data presented in Table III . The mean values for the four rats with respect to the number of p53-positive hepatocytes/mm 2 EAF tissue are given. It can be seen that the number of p53-positive cells was similar in small and medium EAF, but significantly lower in the large EAF. The mean values for the four rats with respect to the ratios of p53 expression in liver tissue and EAF Table II ). d Ratio of p53 expression in non-EAF and EAF tissues. p53 expression in non-EAF and EAF tissue (as shown in Table II ) are also given. Again, there was a noteworthy similarity between the two smaller groups, whereas the larger size category demonstrated a higher ratio. The contribution of the different groups to the total volume fraction is also shown. The large EAF accounted for about half (47%) of the total volume fraction. The material was also divided into other size categories. For example, the large EAF were subdivided into two groups, but this resulted in data from fewer areas, with greater variability and without obvious trends. When the small and medium EAF were subdivided into other categories, results similar to those found for the whole group were obtained. The use of a higher upper size limit for inclusion in the group of medium EAF tended to increase the ratio for this group.
In order to compare directly these in vivo data with in vitro findings we isolated hepatocytes from EAF-bearing rats and studied p53 expression in primary cultures. These experiments were performed essentially as described previously (9, 10) . The challenging dose of DEN was added to the culture medium and p53 staining assessed 24 h after this addition. At this time-point the highest number of positive cells was obtained.
In control experiments immunoprecipitated protein from control and DEN treated primary cultures were prepared for Western blot analysis. A single band was detected by the p53 CM-1 antibody, as shown in Figure 6 . Other antibodies, including Pab 240, were also used and gave similar results (not shown). Parallel cultures with cells from the same rat were immunostained with Pab 240. The fraction of p53 positive cells were 5.5% in the control culture and 18.2% in the DEN culture.
Table V documents data obtained from four donor animals. Rats used for these in vitro experiments received a larger number of weekly injections of DEN and, thus, had higher volume fraction of EAF in their livers than did the rats used in the in vivo experiment. The fact that the mean percentage Percentage of all cells in the culture which were GST-P-positive. c Percentage of p53-positive cells among GST-P-negative and GST-P-positive cells, respectively. d The ratio of the means of p53 expression in non-EAF and EAF cells.
of GST-P-positive cells was higher in the in vitro cultures than the mean volume fraction of EAF in the livers of the four rats used in the in vivo experiment (3.9 Ϯ 1.4, total volume fraction, see Table IV ) supports this assumption. The number of GST-P-negative hepatocytes that became positive for p53 staining in vitro is also given. The mean for the cultures from the four donor animals was 12.8%. On average, 0.25% of the GST-P-positive cells were positive for p53. The ratio between these two means is 51.2.
Discussion
These data demonstrate that expression of wild-type p53 in liver can be studied using immunohistological techniques. Although previous data from non-transgenic mice indicate the reverse (18; cf. also ref. 19) , gamma radiation was used in that study, and more recent studies suggest that gamma radiation is not an efficient inducer of p53 expression detectable by immunohistology in rodent hepatocytes (20) . We have also employed non-standard procedures for fixation and amplifications, not previously used in the present context. The present study also demonstrate that double-staining for p53 and GST-P can be used efficiently, which markedly facilitates a detailed analysis of the distribution of p53-positive hepatocytes. Factors which indicate that the p53 staining is specific include the requirement for a challenging dose of DEN to obtain p53-positive cells, the time-point of most intense staining, the necessity for amplification and rapid fixation, the localization of the staining in the lobule and its co-localization to TUNELpositive cells, selective localization in the hepatocytes (which metabolize DEN to a reactive intermediate with DNA-binding capacity), the subcellular localization to the nucleus and the results of the Western blot analysis. In tumours, positive staining for p53 is usually taken as an indication of the presence of mutations, since these often result in a more stable protein and since mutated cells can be selected for during tumour growth (4) . Nevertheless, we regard the positive staining discussed here as indicative of an accumulation of wild-type protein (a possible exception being the large p53-positive EAF found in rat no. 2). The major arguments for this conclusion are that we observed the positive cells primarily in non-EAF tissue and only after a challenge with DEN, and that the response in non-EAF tissue was similar to that seen in rats free of EAF. Additional considerations include the fact that mutations are rare in rat liver tumours (7) .
We have previously estimated that DNA damage caused by 1236 DEN in vitro is four times more common in GST-P-negative rat hepatocytes than in GST-P-positive hepatocytes (9) . This value is supported by in vivo data on DNA adducts in 2-acetylaminofluorene-treated rats. Using 32 P-post-labelling, it was found that such adducts were 3.1 times more common in 'surrounding' liver tissue than in altered liver tissue (21) . Together, these data suggest that factors inside the cell affecting kinetics [i.e. altered metabolism of xenobiotics and the possible expression of the MDR gene (22)], are a significant protective factor conferring resistance to the formation of DNA adducts in EAF cells; whereas such factors as possible alterations in blood flow may not be involved in resistance. Is the increase in p53 levels in response to a given amount of DNA damage different in EAF and non-EAF hepatocytes? The data presented here strongly suggest that this is, indeed, the case. On an average, non-EAF tissue exhibited an~15-fold higher frequency of p53-positive hepatocytes than did EAF (Table II) . If alterations in drug metabolism can only account for a 3-4-fold difference, the remainder of the change must involve other mechanisms. It thus seems reasonable to propose that there are alterations in the signal transduction pathway connecting DNA damage to subsequent p53 accumulation in most EAF cells. The finding that the frequency of p53 expression in large EAF was Ͼ30-fold less than that in non-EAF tissue supports this idea, as does the finding that even necrogenic doses of DEN do not induce p53 in many EAF ( Figure 5 ).
In the in vitro cultures the ratio between the level of p53 response in GST-P-negative and GST-P-positive hepatocytes upon exposure to DEN was~50. Even though this value is higher than the ratio calculated for all EAF in situ, we consider these two ratios to be in relatively good agreement. The in vitro and in vivo protocols employed here differed in many ways. The apparent discrepancies observed may easily be explained by indications that the rats used in the in vitro experiments had larger EAF or by technical differences with respect to the challenging dose of DEN employed, and effects arising from the isolation and culturing procedures themselves.
The finding that most larger EAF had a lower level of p53-positive cells, than did smaller EAF cannot be explained by, for example, circulatory differences (cf. ref. 23 ). This is indicated by the data on DNA damage discussed above, as well as by the data suggesting that there were fewer p53-positive EAF cells in vitro than in vivo. Instead, the low level of p53 expression in large EAF supports the hypothesis that there are alterations in p53 function that confer growth advantages. The data suggest that hepatocytes in EAF with an attenuated p53 response to DEN, in particular hepatocytes located in EAF Ͼ0.06 mm 2 , may replicate and expand their clones, while other hepatocytes are prevented from replicating by DEN treatment. This reasoning is also discussed by Gijssel et al. (15) .
It may be speculated that when DEN treatment is terminated, many of these cells are effectively eliminated by apoptosis. If the DEN treatment is continued, tumours may develop within a few months. In light of the present data, it seems quite possible that these tumours derive from expanding clones of EAF cells with an attenuated p53 response and inadequate protection of their genome. This scenario is supported by studies on the regulation of hepatocyte growth in the absence of p53. In p53 null mice, hepatocytes are more prone to replicate in response to stress, e.g. liver necrosis. At the same time, hepatocytes isolated from p53 expression in liver tissue and EAF these mice demonstrate an increased 'basal' rate of cell proliferation in primary culture (24) . Also of relevance is the fact that mutated p53 alleles are rarely found in hepatocarcinomas in rodents (7) .
It is possible that the findings presented here are not typical for all types of EAF. DEN may alkylate DNA, as well as inducing 8-hydroxyguanine formation, and DEN adducts remain in the liver for a long period of time (17) ; such characteristics might profoundly affect the results obtained. Preliminary results in our laboratory suggest that EAF in phenobarbital-treated rats can respond to a challenging dose of DEN by inducing p53. More data of this kind may provide additional information about how p53 expression is altered in DEN-induced EAF. Studies on possible changes in patterns of DNA methylation might also provide useful information. It has been shown that DNA methylation can be influenced by 8-hydroxyguanine adducts (25) . In addition, there are stagerelated fluctuations in the methylation pattern in the p53 gene during tumour development in rat liver (26) . Furthermore, WAF expression in DEN-induced EAF seems to be low (27) and it has recently been proposed that p21 WAF might act as a negative regulator of DNA-methyltransferase activity in early stages of the cell cycle (28) .
